From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

H4 antagonist 48   Click here for help

GtoPdb Ligand ID: 9879

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 48 is an orally active, selective histamine H4 receptor antagonist that was developed as a potential therapy for the pruritis and inflammation associated with atopic dermatitis [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

H4 antagonist 48 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 84.13
Molecular weight 334.03
XLogP 2
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CNC1CN(C1)c1nc2ncc(cc2n2c1nnn2)Br
Isomeric SMILES CNC1CN(C1)c1nc2ncc(cc2n2c1nnn2)Br
InChI InChI=1S/C11H11BrN8/c1-13-7-4-19(5-7)10-11-16-17-18-20(11)8-2-6(12)3-14-9(8)15-10/h2-3,7,13H,4-5H2,1H3
InChI Key ICGICUHMULRYIQ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Cowden JM, Zhang M, Dunford PJ, Thurmond RL. (2010)
The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation.
J Invest Dermatol, 130 (4): 1023-33. [PMID:19907432]
2. de Esch IJ, Thurmond RL, Jongejan A, Leurs R. (2005)
The histamine H4 receptor as a new therapeutic target for inflammation.
Trends Pharmacol Sci, 26 (9): 462-9. [PMID:16054239]
3. Fung-Leung WP, Thurmond RL, Ling P, Karlsson L. (2004)
Histamine H4 receptor antagonists: the new antihistamines?.
Curr Opin Investig Drugs, 5 (11): 1174-83. [PMID:15573868]
4. Ko K, Kim HJ, Ho PS, Lee SO, Lee JE, Min CR, Kim YC, Yoon JH, Park EJ, Kwon YJ et al.. (2018)
Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
J Med Chem, 61 (7): 2949-2961. [PMID:29579390]
5. Ohsawa Y, Hirasawa N. (2012)
The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice.
Allergy, 67 (8): 1014-22. [PMID:22686688]
6. Suwa E, Yamaura K, Oda M, Namiki T, Ueno K. (2011)
Histamine H(4) receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model.
Eur J Pharmacol, 667 (1-3): 383-8. [PMID:21664903]